Oct 3
Over the past decade, the number of U.S. trials labeled “pragmatic” has increased significantly. Once viewed as an approach with limited applicability, pragmatic trials are being looked at as an opportunity to expand access to trials, and an efficient way to answer regulatory questions. Introducing pragmatic elements such as simplified procedures and expanding eligibility criteria make it possible to collect data at the point of care that can answer questions important to regulators while also informing clinical care decisions at the bedside.
Read the full article featuring Rob DiCicco from Healthcare Business Today here.
Related Blog Posts
Making AI work where it matters, with Rob DiCicco
In a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, for a conversation on the barriers and the breakthroughs in making AI work in drug development and clinical trials. Read the full article featuring Rob DiCicco from Pharmaphorum here.
From Vision to Value: A Blueprint for Implementing Industry Consortia Innovations
Our healthcare landscape is rapidly evolving and presenting us with complex challenges: modernizing clinical trials, ethically integrating artificial intelligence, and delivering patient-centric care. No single organization can tackle these issues alone. Read the full article from DIA Global Forum here.
TransCelerate Highlights Digital Momentum and Global Collaboration in 2025 Annual Report
TransCelerate BioPharma has released its 2025 annual report, titled The Power of Forward, outlining a year defined by continued digital adoption, regulatory collaboration, and expansion of pragmatic approaches to clinical development. Read the full article featuring Janice Chang from Applied Clinical Trials here.